MOLOGEN AG
Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG (news with additional features)
MOLOGEN AG / Key word(s): Change of Personnel PRESS RELEASE N 11 / 2015 of 07/23/2015 Dr. med. Mariola Söhngen will be the new CEO of Berlin, July 23, 2015 – The Supervisory Board of biotechnology company MOLOGEN AG today appointed Dr. Mariola Söhngen as Member of the Executive Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from November 1, 2015. Dr. Söhngen is co-founder of PAION AG and PAION Deutschland GmbH. She will remain at PAION in her role as Chief Medical Officer (CMO) up to October 31, 2015, with responsibility for phase I to IV clinical development, regulatory and approval issues, pharmaceutical drug safety, quality assurance, project management, Human Resources (HR), Intellectual Property (IP) as well as preclinical research and development. In addition, Dr. Söhngen played a decisive role in the company’s successful financing and licensing agreements. When she assumes the role of CEO at MOLOGEN, she will be in charge of Research, Business Development, Strategy and Partnering. Dr. Matthias Schroff will resign from his post as chairman of the Executive Board on October 31, 2015 and will be leaving the Executive Board with effect from December 31, 2015, by mutual agreement with the Supervisory Board. In the interim period from November 1, 2015 to December 31, 2015, Dr. Schroff intends to provide support as an Executive Board Member, cooperating with Dr. Söhngen to ensure a smooth transition of the chairmanship. In addition, Jörg Petraß (Chief Financial Officer; CFO) also took the decision in mutual agreement to not extend his contract, which is due to expire on December 31, 2015, and will be leaving the Executive Board. However, he has offered to act as a consultant for a transitional period to enable orderly succession planning and the induction of his successor. Oliver Krautscheid, Chairman of the Supervisory Board of MOLOGEN AG: “We are delighted that Dr. Söhngen, an extremely competent biotech and pharma manager, has agreed to take on the post of CEO. As co-founder of a successful listed German company, she has already proved her credentials as an entrepreneur in the biotech and pharma sector. She is a renowned biotech and pharma expert, who has acquired a wealth of experience in clinical research through to the approval of pharmaceutical products and has negotiated several successful in- and out-licensing deals. This means she is an ideal choice for the post of CEO, in order to lead MOLOGEN AG through the transformation process from a research-based biotech company to a biopharmaceutical product company. We would like to extend our special thanks to Dr. Schroff and Mr Petraß for their many years of service for the good of the company and wish them all the best for the future.” Dr. Söhngen: “MOLOGEN has an impressive development pipeline” MOLOGEN AG The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. For more information on the trials please visit www.clinicaltrials.gov. With unique, patented technologies and innovative products, MOLOGEN is pioneering immuno- therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
+++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=QJFETHVUAE Document title: Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG 2015-07-23 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News-Service |
380603 2015-07-23 |